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Methylation of lysine-4 of histone H3 (H3K4men) is an important regulatory factor in eukaryotic transcription.
Removal of the transcriptionally activating H3K4 methylation is catalyzed by histone demethylases, including
the Jumonji C (JmjC) KDM5 subfamily. The JmjC KDMs are Fe(II) and 2-oxoglutarate (2OG)-dependent
oxygenases, some of which are associated with cancer. Altered levels of tricarboxylic acid (TCA) cycle
intermediates and the associated metabolites D- and L-2-hydroxyglutarate (2HG) can cause changes in
chromatin methylation status. We report comprehensive biochemical, structural and cellular studies on the
interaction of TCA cycle intermediates with KDM5B, which is a current medicinal chemistry target for cancer.
The tested TCA intermediates were poor or moderate KDM5B inhibitors, except for oxaloacetate and
succinate, which were shown to compete for binding with 2OG. D- and L-2HG were moderate inhibitors at
levels that might be relevant in cancer cells bearing isocitrate dehydrogenase mutations. Crystallographic
analyses with succinate, fumarate, L-malate, oxaloacetate, pyruvate and D- and L-2HG support the kinetic
studies showing competition with 2OG. An unexpected binding mode for oxaloacetate was observed in which
it coordinates the active site metal via its C-4 carboxylate rather than the C-1 carboxylate/C-2 keto groups.
Studies employing immunofluorescence antibody-based assays reveal no changes in H3K4me3 levels in cells
ectopically overexpressing KDM5B in response to dosing with TCA cycle metabolite pro-drug esters,
suggesting that the high levels of cellular 2OG may preclude inhibition. The combined results reveal the
potential for KDM5B inhibition by TCA cycle intermediates, but suggest that in cells, such inhibition will
normally be effectively competed by 2OG.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Dynamic changes in post-translational modifications
to chromatin, in particular to the N-terminal tails of
histoneH3, contribute to the regulation ofmany cellular
functions and modulate transcription in both healthy
and diseased states [1–3]. Histone H3 lysine 4 (H3K4)
methylation is an importantmodification that is normally
activating with respect to transcription [4]. Removal of
the H3K4 methylation regulates expression and is
performed by histone demethylases from two differentuthors. Published by Elsevier Ltd. This is a
rg/licenses/by/4.0/).families [5]. The flavin adenine dinucleotide-dependent
demethylases LSD1/2 (KDM1 family) specifically
catalyze demethylation of di- and mono-methylated
states of H3K4 (H3K4me1 and H3K4me2), while all
methylated states of H3K4 (H3K4me1, H3K4me2
and H3K4me3) are substrates for the KDM5 family of
demethylases, also knownas the JARID1s [1,6,7]. The
KDM5 family contains the Jumonji C (JmjC) domain
and belongs to the superfamily of Fe(II)/2-oxoglutarate
(2OG)-dependent oxygenases [8,9]. The 2OG
oxygenases use Fe(II) as a cofactor and 2OG as
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and CO2 is coupled to oxidation of methylated lysine
residues in histone substrates to give hemiaminal
intermediates, subsequent decomposition of which
results in the formation of the corresponding demethy-
lated lysine residue and formaldehyde [10].
The human KDM5 family comprises four isoforms
(KDM5A-D), which in addition to the catalytic JmjC
domain also contain an N-terminal Jumonji N-domain,
a deoxyribonucleic acid (DNA)-binding ARID domain,
a C5HC2 zinc finger, a PLU1-motif and two or
three PHD domains [8,11,12]. KDM5 demethylation
activity is involved in regulating cell differentiation and
proliferation (KDM5A and KDM5B) and has been
related to disease states, especially cancer [1,13].
The KDM5 enzymes have roles in tumor initiation,
maintenance/survival and development of drug
resistance [13,14]. KDM5A (JARID1A, RBP2) is a
retinoblastoma RB-binding protein and mediates
metastasis in estrogen receptor-negative breast
cancers [15], while KDM5B (JARID1B or PLU-1) has
roles in tumor maintenance [16], melanoma metasta-
tic progression and resistance to cytotoxic agents and
BRAF inhibitors [13]. KDM5C is involved in neuronal
development [17], andKDM5D,which is encoded by a
Y-chromosome-encoded (male specific) gene, has a
role in spermatogenesis [18], Consequently, KDM5
members are current medicinal chemistry targets
for cancer, with KDM5B being a particular focus due
to its role in tumor maintenance and progression
[13].
The JmjC demethylases employ 2OG as a
co-substrate and have potential to be inhibited by
structurally related tricarboxylic acid (TCA) cycle
metabolites [19]. Previous work has shown inhibition
of certain 2OG oxygenases by succinate, fumarate
[20–24] or D-/L-2-hydroxyglutarate (D-/L-2HG)
[25–27], including the histone demethylase KDM4A
[28,29]. These observations are of interest since
mutations to genes encoding for succinate dehydro-
genase or fumarate hydratase in cancer cells lead to
the accumulation of succinate or fumarate, the
metabolic changes that have been associated with
tumorigenesis [30–32]. Elevated succinate and
fumarate levels occur in paragangliomas, pheochro-
mocytomas, gastric tumors (succinate) and heredi-
tary leiomyomatosis (fumarate) [33,34]. “Gain of
function” mutations to genes encoding for isocitrate
dehydrogenase 1 or 2 (IDH1/2) in various tumors
and leukemia lead to accumulation of high levels of
D-2HG [35–37]. It is proposed that accumulation of
some TCA cycle metabolites/2HG promotes tumor-
igenesis by altering modifications to chromatin,
including histone and DNA methylation patterns
[34]. Accumulation of D-2HG in cells has been
reported to affect the H3K9 and H3K27 methylation
status [38,39], and succinate dehydrogenase/
fumarate hydratase mutant tumors have been linked
to global increases inDNAmethylation/hydroxymethy-lation levels [40,41]. Thus, the effects of TCA cycle
metabolites on the levels of other histone methylation
marks, including transcriptionally important H3K4
methylation, merit detailed investigation.
We report studies on the enzyme activity inhibition
of isolated KDM5B, a current medicinal chemistry
target, by TCA cycle metabolites and D- and L-2HG.
Kinetic studies revealed a large difference in the
extent of inhibition, with oxaloacetate and succinate
being the most potent of the tested compounds.
Crystallographic analyses support the findings sug-
gesting competition of TCA cycle intermediates with
2OG and reveal an unexpected coordination mode
for oxaloacetate. In contrast with some of the other
2OG oxygenases acting on chromatin, cellular
studies on the effects of elevated TCA cycle
metabolites on H3K4 methylation imply that the
relatively high 2OG levels may “outcompete” the
elevated TCA intermediate levels.Results
In vitro biochemical studies show inhibition of
KDM5B by succinate and oxaloacetate
We initially investigated inhibition of purified
recombinant KDM5B (produced in Sf9 insect cells,
M1-R822) by TCA cycle metabolites. KDM5B cata-
lyzes demethylation of H3K4me3, H3K4me2 and (with
lower activity) H3K4me1; in linewith the previouswork,
the H3K4me2(1–21) peptide fragment was chosen
for inhibition studies to avoid complications due to
sequential demethylation that is observed when using
the analogous H3K4me3 peptide [8]. Previous kinetic
studies on KDM5B and H3K4me2 were conducted
using a formaldehyde dehydrogenase (FDH)-coupled
assay using 15-mer and 21-mer H3 peptide frag-
ments, and recombinant truncated KDM5B con-
structs, without the PLU1, PHD2 and PHD3 domains
(KDM5B(1–769) or KDM5B(1–822) [8,42]). Reported
Km
app(2OG) and Km
app(H3K4me2(1–15)) were 6 and
3.6 μM, respectively [42], whereas the Km
app for
H3K4me2(1–21) was 0.85 μM [8]. The differences in
the reported Km
app values may be attributed, at least in
part, to different lengths of the peptide substrates as
precedented in work with other 2OG oxygenases
[43–45].
We used matrix-assisted laser desorption/
ionization–time of flight–mass spectrometry (MALDI-
TOF-MS) for direct analysis of methylated and
demethylated peptide ratios (by analyzing peak
intensities), to avoid the possibility of FDH inhibition
which could interferewith results whenusing theFDH-
coupled enzyme assay. As a prelude to the inhibition
studies, Km
app values for 2OG and H3K4me2(1–21)
peptide were determined for KDM5B(1–822) using
MALDI-TOF-MS to identify appropriate experimental
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were Km
app(2OG) = 2.6 ± 0.6 μM, Km
app(H3K4me2(1–
21)) was ~0.5 μM and the kcat
app was 0.015 ± 0.01 s−1
(Supplementary Information, Fig. S1). Thus, the
results of our Km
app(H3K4me2(1–21)) determination
are in agreement with the previously reported FDH-
based results [8]. The Km
app(H3K4me2) for the 21-mer
peptide was lower than the MALDI-TOF-MS limit
of detection, which prevented a more accurate
determination.
The inhibition of TCA cycle metabolites was then
assessedbydetermining the IC50 valueswith the 2OG
concentration fixed at the Km
app(2OG) level (3 μM) and
saturating levels of H3K4me2(1–21) peptide substrate
(5 μM). The highest levels of inhibition were observed
in the presence of oxaloacetate (IC50 15 ± 10 μM;
Table 1, Supplementary Information Fig. S2) and
succinate (IC50 62 ± 19 μM; Table 1). For pyruvate,
citrate and isocitrate,millimolar levelswere required to
observe inhibition (if any) (IC50 703 ± 26 μM for
pyruvate, N1 mM for citrate/isocitrate). D- and
L-2HG inhibited KDM5B-catalyzed demethylation
with IC50 values in a range of 150–200 μM, that is,
less potently than for some other reported histone
demethylases (e.g., KDM4A, the IC50 values for both
D- and L-2HG ~25 μM) [28]; these values, however,
do not exclude inhibition in tumor cells where D-2HG
levels can reach the mM range [46].
We then determined inhibitory constants (Ki) for
succinate and oxaloacetate using the MALDI-TOF-MS
assay with respect to 2OG. Km
app for 2OG was
assessed in the presence of different concentrations
of succinate and oxaloacetate (Fig. 1, Table 2); the
data fitted best to a competitive inhibition model using
non-linear regression (more details are given in the
Supplementary Information, Tables S1–S3). The
results showed an increase in Km
app for 2OG in the
presence of inhibitor [from 3 μM (no inhibitor) to
44 μM at 300 μM succinate, and to 18 μM at 100 μM
oxaloacetate], while the Vmax values remained the
same, revealing that both succinate and oxaloacetateTable 1. Inhibition of KDM5B by TCA cycle intermediates
Compound IC50 (μM)
Succinate 62 ± 19
Fumarate 210 ± 80
D-2HG 203 ± 90
L-2HG 150 ± 40
Malate 127 ± 72
Citrate Inactive (18% inhibition at 1 mM)
Pyruvate 703 ± 26
Oxaloacetate 15 ± 10
Isocitrate Inactive (10% inhibition at 1 mM)
IC50 values for KDM5B byTCA cyclemetabolites. Assay conditions:
0.6 μM KDM5B, 3 μM 2OG, 5 μM H3K4me2(1–21), 10 μM Fe(II),
500 μML-ascorbate in 50 mMHepes, 50 mMNaCl (pH 7.5). Errors
represent 95% confidence intervals. The levels of methylated and
demethylated peptides were analyzed using MALDI-TOF-MS.inhibit KDM5B in a 2OG competitive manner. The
determined Ki values were 27 ± 6 μM for succinate
and 54 ± 6 μM for oxaloacetate.
Co-crystal structures of complexes of KDM5B
with TCA cycle metabolites provide evidence for
2OG competitive binding
To investigate the mode of binding of the TCA
cycle metabolites to KDM5B, we utilized recombi-
nant KDM5B (F26-K772) lacking its ARID and PHD1
domain, which we have previously successfully used
in crystallization studies [8]. Crystals of the
KDM5B·Mn(II) complex were soaked with either
2OG, succinate, fumarate, malate, oxaloacetate,
pyruvate, D- and L-2HG, citrate, or isocitrate. Ligand
structure complexes were obtained for all intermedi-
ates (resolutions 1.8–2.5 Å), except for citrate and
isocitrate (Fig. 2), consistent with the observed
weak binding and absence of inhibition for these
compounds.
It has been previously reported that 2OG is bound
at the active site of KDM5B in a manner typical for
other 2OG oxygenases, including the JmjC subfam-
ily [8,47,48]; 2OG coordinates the active site metal in
a bidentate manner via one of its C-1 carboxylate
and C-2 keto oxygens. Octahedral metal coordina-
tion is completed by His587, His499 and Glu501,
and a water molecule (W3, Fig. 2a). According to the
consensus mechanism for 2OG oxygenases, bind-
ing of the metal bound water is weakened on
substrate binding, hence promoting the formation
of a vacant coordination site for dioxygen to bind
[10]. In addition to binding the metal, the Glu501
side-chain carboxylate may be involved in interac-
tions with, and the positioning of, the Nε-methyl
lysine group of the substrate. The C-1 carboxylate of
2OG is further stabilized by hydrogen bonding with
Ser507, which may be involved in 2OG decarboxyl-
ation/loss of CO2 during catalysis [8]. The C-5
carboxylate of 2OG is positioned to form electrostatic
interactions with Lys517 and Asn509, via one of its
oxygens, whereas the other C-5 carboxylate oxygen
forms a hydrogen bonding interaction with the
hydroxyl of Tyr425. The side chains of Trp514 and
Phe496 are positioned to clamp the C-3 and C-4
methylenes of 2OG via hydrophobic interactions.
The studied TCA cycle intermediates all bind in the
2OG pocket (Fig. 2b–h). All, except for D-2HG, are
positioned to form electrostatic interactions with
Lys517 in an approximately similar position to that
of the C-5 2OG carboxylate. In the case of succinate
and fumarate, the C-5 2OG carboxylate equivalent is
positioned to form additional interactions with the
hydroxyl group of Tyr425 (Fig. 2e, f). For all the other
ligands, the Tyr425 side chain is directed away from
the active site (Fig. 2b–d, g–h). Asn509, which has
previously been observed to adopt more than one
conformation [8], is involved in the formation of
Fig. 1. Determination of Ki values for inhibition of KDM5B by succinate (a) and oxaloacetate (b). Assay conditions: 0.6 μM
KDM5Bwas incubated with various concentrations of 2OG, 5 μMH3K4me2(1–21), 10 μMFe(II), and 500 μML-ascorbate and
different concentrations of succinate (0, 30, 100 and 300 μM) or oxaloacetate (0, 15, 50 and 100 μM), buffer: 50 mM Hepes,
50 mM NaCl (pH 7.5). Error bars represent the SD for triplicate assays. The levels of methylated and demethylated peptide
were analyzed usingMALDI-TOF-MS. Analysis of datawas performed usingGraphPadPrism5.0 (Supplementary Information,
Tables S1–S3). C. Structures of the TCA cycle intermediates investigated as KDM5B inhibitors.
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carboxylates of the ligands (Fig. 2). In the succinate
complex, Asn509 is located as observed for 2OG
and is positioned to form interactions with both
succinate carboxylates (Fig. 2e). In the other
complex structures, except that for pyruvate, the
Asn509 side chain is positioned to form interactions
between its primary amide and the ligand carboxyl-
ate equivalent to the 2OG C-2 carboxylate (2.9–
3.5 Å). In the pyruvate complex, the Asn509 amide
nitrogen is instead positioned to form electrostatic
interactions (distance 3.1 Å) with C-2 ketone car-
bonyl oxygen.
Interestingly, in the case of oxaloacetate, the
ligand binds such that its C-4 carboxylate, rather
than its 2-oxoacid (as observed with 2OG), ligates to
the metal. This binding mode should enable discrim-
ination between oxaloacetate and 2OG with respect
to oxidative decarboxylation. It may reflect a form of
negative catalytic regulation; that is, oxaloacetate
binds in a catalytically non-productive manner to
avoid oxidative decarboxylation. Like oxaloacetate,
pyruvate binds with its carboxylate occupying the
2OG C-5 carboxylate equivalent position; however,
the ketone oxygens of oxaloacetate and pyruvate
project in opposite directions.The binding of L-2HG is similar to that of 2OG,
with the C-2 hydroxyl group occupying a similar
position to the C-2 carbonyl of 2OG and the C5
carboxylate is found in an identical position. How-
ever, in the case of D-2HG, the C-5 carboxylate is
rotated out of the binding pocket to form interactions
with water molecules (W3, W7 and W11), while its
C-1 carboxylate and C-2 OH-group bind similarly as
in 2OG (Fig. 2c).
Different solvation patterns relative to 2OG
were observed for the studied ligands, with
additional water and, sometimes, ethylene glycol
molecules present within the 2OG binding pocket
(Fig. 2), likely reflecting the weak binding of the
relevant ligands. Additional water molecules were
sometimes observed/refined in the metal or C-1
2OG carboxylate binding region, in some cases
likely due to the smaller size of the bound ligand
relative to 2OG (e.g., pyruvate; Fig. 2b); in other
cases, they may reflect additional/altered hydro-
gen bonding opportunities enabled by the ligand
structure (e.g., L-2HG/D-2HG; Fig. 3c, d). The
β5–β6 loop, which contains the JmjN–ARID
linkage, is found to be ordered only in the crystal
structure in complex with pyruvate and is posi-
tioned as reported [8].
Table 2. Kinetic parameters for KDM5B
Km(2OG)
app (μM) Km(H3K4me2(1–21))
app (μM) kcat (s
−1) Ki (succinate; μM Ki (oxaloacetate; μM)
KDM5B 2.6 ± 0.6 ~0.5 0.015 ± 0.01 27 ± 6 54 ± 6
Assay conditions: 0.6 μM KDM5B. Variable concentrations of 2OG and H3K4me2(1–21) peptide: 10 μM Fe(II), 500 μM L-ascorbate in
50 mM Hepes, 50 mM NaCl (pH 7.5). Errors represent 95% confidence intervals. The levels of methylated and demethylated peptides
were analyzed using MALDI-TOF-MS.
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metabolites in cells do not show elevated levels
of H3K4me3
The cellular effects of dimethyl ester precursors of
TCA cycle-related metabolites as potential inhibitors
of H3K4me3 demethylation were then assessed. We
used an established immunofluorescence (IF) pro-
cedure with ectopically overexpressed wild-type
KDM5B (WT KDM5B) in U2-OS cells and anti-
H3K4me3 antibody monitoring for changes in
H3K4me3 methylation levels [49]. The demethylation
activity of WT KDM5B in cells was compared to that
of its catalytically inactive variant (H499A/E501A,
hereafter, KDM5B Mut) [50]. Cells with overexpressedFig. 2. Views from crystal structures of KDM5B in complex
and D-2HG. Residues in the active site of KDM5B are shown a
and L- and D-HG (c and d) are shown as yellow sticks. Mn(II)
water molecules as red spheres. Ethylene glycol derived from
map for the ligands is contoured at 1σ. The arrows reflect the T
elevated due to mutations to DNA encoding for isocitrate dehyKDM5B were treated with different concentrations
of the TCA cycle-related pro-drug esters (previously
established as cell permeable in other cell-based
studies) [28,51–54] for 24 h, the H3K4me3 levels
were then analyzed in the transfected cells. The
reported KDM5B inhibitor KDOAM-25 ((2)-((((2)-(((2)-
(dimethylamino)ethyl)(ethyl)amino)-(2)-oxoethyl)ami-
no)methyl)isonicotinamide) was used as a positive
control for inhibition [50,55]. Comparison of cells
transfected with WT KDM5B or KDM5B Mut express-
ing vectors showed the expected decrease in
H3K4me3 levels in the WT transfected cells (Fig. 3).
We first investigated potential changes in H3K4me3
levels in response to different concentrations of
dimethyl-2OG (Fig. 3a). No decrease in the H3K4me3with TCA cycle intermediates and the oncometabolites L-
s green sticks, whereas the TCA intermediates (a–b, e–h)
(substituting for Fe(II)) is shown as an purple sphere, and
the cryoprotectant is shown in orange sticks. The 2Fo–Fc
CA cycle and associated reactions (e.g., D-2HG levels are
drogenases).
Fig. 3. TCA cycle-related metabolites (administered as pro-drug esters) do not inhibit the activity of over-expressed
KDM5B in U2-OS cells. EC50 curves for cells overexpressing Flag-tagged KDM5B. IF assay showing the effects of WT
KDM5B-mediated H3K4me3 demethylation in comparison to its inactive mutant (Mut KDM5B). Results for dimethyl-2OG
(a), dimethyl-succinate (b), dimethyl-D-2HG (c), dimethyl-L-2HG (d), octyl-D-2HG (e), octyl-L-2HG (f), and KDOAM-25 (g).
Dashed lines represent IF levels in non-inhibitor controls.
2900 Interaction studies of KDM5B with TCA cycle intermediateslevels was observed, suggesting that 2OG levels
are saturating for KDM5B activity in the tested cells.
Although other factors may be involved in cells,
this observation is consistent with the relatively low
Km
app(2OG) (3 μM) for KDM5B determined with
isolated recombinant KDM5B. The esters of the TCA
cycle metabolites (dimethyl-2OG, dimethylfumarate,
dimethyl-D-/dimethyl-L-2HG, octyl-D-/octyl-L-2HG)
were thus dosed up to 5–10 mM concentration. In
contrastwith the experimentswith isolated KDM5B, no
inhibition of KDM5B activity was observed (Fig. 3b).
Dimethylfumarate was toxic at concentrations higher
than 400 μM and did not show any inhibition at lower
concentrations (data not shown). Inhibition by oxalo-
acetate in cells was not studied due to its unstable
nature [56]. By contrast, KDOAM-25 (a potent positivecontrol inhibitor, IC50 value is 19 nM against isolated
KDM5B as determined by AlphaScreen assay [55])
manifested the expected levels of inhibition, with
H3K4me3 fluorescence reaching levels of KDM5B
Mut at compound concentration of 1 mM (Fig. 3g).
Thus, 2OG competitive inhibition (as observed by
kinetics and crystallography) may mitigate the inhib-
itory effects of the elevated levels of the studied TCA
cycle-related compounds in cells.Discussion
Although the inhibition of 2OGoxygenases involved
in chromatin regulation by TCA cycle intermediates
and D-/L-2HG has been widely considered as of
2901Interaction studies of KDM5B with TCA cycle intermediatesrelevance in tumor biology, there are few systematic
biochemical studies. Our results on the interaction of
TCA cycle-related metabolites with isolated KDM5B
reveal the potential for its inhibition by some, but not
all, of the tested compounds, including D-2HG, levels
of which are elevated in cancer cells due to mutations
to IDH1/2 [46].
Crystal structures of KDM5B complexed with
manganese (substituting for iron) and the TCA
cycle-related metabolites reveal that most of the
compounds have the potential to inhibit KDM5B, and
by implication other KDM5 subfamily enzymes, in a
2OG competitive manner. Although, all of the inhibit-
ing metabolites occupy the 2OG binding site, they
exhibit variations in their binding modes, which
appears to correlate with the observed potencies.
Thus, pyruvate was shown to be a very weak KDM5B
inhibitor and did not manifest metal chelation in its
bindingmode. Citrate and isocitrate were also inactive
as KDM5B inhibitors under the studied assay condi-
tions, consistent with our inability to obtain crystal
structures for them.
The crystal structures provide evidence that the
conformations of the 2OG binding pocket in KDM5B
are relatively flexible (as manifested by the observed
alternative conformations for Tyr425 and Asn509 [8])
compared to other JmjC oxygenases (e.g., the KDM4
subfamily D-/L-2HG, PDB ID: 2YBK and 2YBS,
respectively). This property apparently enables the
2OG binding pocket in KDM5B to adapt to the different
shapes of the various TCAcycle-related intermediates.
The conformations of the 2OG binding pocket
residues in complexes of D- and L-2HG with
KDM4A [28] are similar to those observed for
KDM5B (notably KDM4A-Ser288/KDM5B-Ala599,
Fig. 4c, d); L-2HG binds in the same conformation
to both enzymes; however, the C-5 carboxylate of
D-2HG in KDM5B points toward the metal, forming
water-mediated interactions, rather than the elec-
t r o s t a t i c i n t e r a c t i o n w i t h c o n s e r v e d
KDM4A-Lys206 (Fig. 4c, d). Notably, the trimethy-
lated lysine in the H3K36me3(30–41) present in a
L-2HG complex with KDM4A (PDB ID: 2YBS),
superimposes with an ethylene glycol molecule
present in all the KDM5B complexes, suggesting
that the ethylene glycol occupies part of the
position of the peptide substrate in the KDM5B
active site.
Of the tested metabolites, succinate and oxaloace-
tate showed the highest potency for KDM5B inhibition,
with IC50 values of 15 ± 10 and 62 ± 19 μM, respec-
tively. While oxaloacetate has not been reported to
accumulate under pathological conditions, increased
succinate levels are established in certain cancers
[19]. Comparison of the D-/L-2HG inhibition potencies
for different 2OG oxygenases (Table 3) suggests that
they differently affect human members of the 2OG
oxygenase superfamily [as may also be the case for
other (combinations of) TCA cycle-related metabo-lites]. Notably, D-2HG and L-2HG showed lower levels
of KDM5B inhibition compared to that reported for
KDM4A (obtained IC50 values of 203 ± 90 μ and
150 ± 40 μM for D-/L-2HG, respectively, compared to
25μM for KDM4A; Table 3), consistent with our cellular
results [28]. However, D-2HG levels can reach mM
concentrations in cells, as seen in IDH1/2 mutations;
thus, metabolite-specific inhibition of KDM5B (and by
implication other KDM5members) byD-2HG in tumors
cannot be ruled out. Itmay alsobecome relevant under
cellular conditions when 2OG concentrations are
reduced, such as in tumor cells where mutations to
the TCA cycle enzymes disrupt the TCA cycle
metabolite ratios [39,46,59].
In contrast with the results for some other 2OG
oxygenases (e.g., the KDM4 demethylases and the
TET enzymes) [22,28,39,53], our cellular results (with
over-expressed KDM5B) imply that KDM5B is not, at
least strongly, regulated by changes in levels of the
tested metabolites. We did, however, observe inhibi-
tion with the potent KDM5B inhibitor KDOAM-25.
Changes in the intracellular levels of 2OG are
proposed to influence 2OG oxygenase activity [38];
there are also considerable variations in the Km
app
values for 2OG reported for 2OG oxygenases, which
likely also influence their 2OG competitive inhibition.
However, treatment of U2-OS cells with increasing
amounts of dimethyl-2OG did not show any effect on
the activity of ectopically overexpressed KDM5B to
demethylate H3K4me3, suggesting that under the
tested conditions, the intracellular 2OG levels are
saturating for KDM5B catalysis. This result is
consistent with the relatively low Km
app(2OG) for
KDM5B (3 μM), which is likely below intracellular
2OG concentrations [60].
Thus, although there are caveats on the physio-
logical relevance of our cellular work with KDM5B
(as with that for other JmjC KDMs), the available
evidence is that some JmjC KDMs and, by
implication histone marks, may be more suscepti-
ble to changes in specific metabolite concentrations
than others (e.g., D-2HG, succinate or fumarate as
can occur in tumors). The overall results, however,
raise the possibility of regulation of KDM5 activity by
competition for 2OG binding by multiple metabo-
lites, the combined concentration of which will be
high relative to 2OG. Such competition by multiple
molecules has the potential to tune enzyme activity
and to provide effects enabled by context- and
time-dependent changes in the competing meta-
bolic composition [61]. Such competition has
been proposed as a regulatory mechanism for
catalysis by the JmjC “hydroxylase” factor inhibiting
hypoxia-inducible factor (FIH) [61]. However, in the
case of FIH, the proposed “multiple-molecule”
competition occurs between one substrate class
“HIF-α isoforms” on which FIH catalysis has a
profound signaling effect and another substrate
class “ankyrins” on which FIH does not have an
Fig. 4. Comparison of the binding modes of TCA intermediates and L- and D-2HG within the 2OG binding pockets of
KDM5B and KDM4A. (a) Overlay of a structure of KDM5B complexed with 2OG (green) or oxaloactetate (yellow). Tyr425
is observed in different conformations, one of which is replaced by solvent molecules in the structure with oxaloacetate.
(b) Overlay of KDM5B complexed with L-2HG (gray) and D-2HG (cyan) showing alternative positions for the C-5 carboxylate.
(c–d) Overlay of L-2HG (c) and D-2HG (d) complexedwith KDM4A (magenta) and KDM5B (D-2HG, cyan; L-2HG, gray). Note
the nearly identical binding modes for the L-2HG with KDM5B and KDM4A, but the different binding modes for the C-5
carboxylate of D-2HG.
2902 Interaction studies of KDM5B with TCA cycle intermediates(identified) signaling role. Competition between HIF
and ankyrins is proposed to regulate hydroxylation of
the former [61].Table 3. Reported results for inhibition of 2OG oxygenases by
Enzyme Enzyme
concentration
(μM) Succinate Fumarate
KDM4A 2 [28] NR NR
KDM4C 1 [28] NR NR
KDM4E 2 [57] 320 [57] 2.3 [57]
KDM2A 2 [28] NR NR
PHD2 0.5 [28] 19 [29] 3 [29]
FIH 1 [28] N1000 [29] N1000 [29]
BBOX 0.025 [28] NR NR
ABH2 2 [28]
TET1 NR 540 ± 100 [22] 390 ± 160 [22]
TET2 NR 570 ± 190 [22] 400 ± 70 [22]
KDM5B 0.6 62 ± 19 210 ± 80
NR, not reported. Note that the assays were carried out under differenFinally, it is important to note that many 2OG
oxygenase inhibitors, including inhibitors in clinical
development and KDM5 subfamily inhibitorsTCA cycle intermediates
IC50 (μM) Km
app(2OG;
μM)
D-2HG L-2HG
24 ± 2 [28] 26 ± 3 [28] 6 [28]
79 ± 7 [28] 97 ± 24 [28] 4 [28]
NR NR 13.2 [58]
106 ± 22 [28] 48 ± 15 [28] 12.5 [28]
7300 ± 3300 [28] 419 ± 150 [28] 13 ± 2 [45]
1500 ± 400 [28] 189 ± 34 [28] 110 ± 20 [45]
13,200 ± 1100 [28] 142 ± 30 [28] 470 [45]
424 ± 77 [28] 150 ± 20 [28] 10 [28]
4000 [26] 1000 [26] 55 ± 20 [22]
5000 [26] 1600 [26] 60 ± 15 [22]
203 ± 90 150 ± 40 2.6 ± 0.6
t conditions, including with respect to enzyme concentration.
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the 2OG binding pocket [23]. The combined results
described here and previously suggest that it is
possible that both the absolute and relative
concentrations of TCA cycle-related intermediates
could influence pharmaceutical inhibitor potency in
vivo.Materials and Methods
Recombinant KDM5B production and purification
Recombinant KDM5B (M1-R822 and F26-K722)
was produced in Sf9 insect cells and purified as
previously described [8].
Crystallization and crystal structure
determinations
A JmjN–JmjC linked construct of KDM5B
(F26-K772) was crystallized using the sitting drop
vapor diffusion method as previously described [8].
Crystals of KDM5B were soaked with final concen-
trations of 10–25 mM of the TCA intermediates
supplemented with 25% (v/v) ethylene glycol for
15 to 120 min and then flash frozen in liquid
nitrogen. Data were collected at Diamond Light
Source beamlines I04-1, I02 and I04. Data sets
were processed using Xia2 [62], molecular re-
placement and initial refinement in DIMPLE pipe-
line [63] (used the PDB ID: 5A1F as a model).
Iterative model building was done using COOT [64]
and refinement with PHENIX [65] and BUSTER
v2.10.1 [66]. Data collection and refinement statis-
tics are given in Table S3, Supplementary
Information.
MALDI-TOF-MS-based enzymatic assays
Kinetic assays were performed in 50 mM Hepes,
50 mM NaCl (pH 7.5) buffer at 25 °C. KDM5B
(0.6 μM) was incubated with various amounts of
2OG and H3K4me2(1–21) peptide (a fragment of
the natural histone/nucleasome substrate), 10 μM
Fe(NH4)2(SO4)2 and 500 μM sodium L-ascorbate.
The reaction was quenched with 1% formic acid at
defined time points. The samples were then mixed in
1:1 ratio with α-cyano-4-hydroxycinnamic acid ma-
trix and spotted onto a MALDI target plate. Spectra
were acquired using MALDI-TOF-MS (Micro MX,
Waters, UK) in reflectron positive mode and proc-
essed using MASSLYNX4.0. Time courses at each
2OG/peptide concentrations were analyzed and
initial rates of demethylation were determined. The
initial rates were plotted versus concentration and
analyzed with the assumption of Michaelis–Menten
kinetics using Origin 8.51 software.Inhibition assays were performed in 50 mM
Hepes, 50 mM NaCl (pH 7.5) buffer at 25 °C.
KDM5B (0.6 μM) was incubated with 3 μM disodium
2OG, 5 μMH3K4me2(1–21), 10 μM Fe(NH4)2(SO4)2
and 500 μM sodium L-ascorbate for 5 min and
subsequently quenched with 1% formic acid. The
samples were mixed in a 1:1 ratio with α-cyano-4-
hydroxycinnamic acid matrix and spotted onto a
MALDI target plate for MS analysis. The demethyla-
tion levels were normalized compared to the non-
inhibitor control. The IC50 values were determined
using GraphPad Prism software. All experiments
were carried out in triplicate.
Cellular assays
Immunofluorescent cell-based assays were per-
formed as reported [50]. The human U2-OS osteo-
sarcoma cells were cultured as a monolayer in
Dulbecco's modified Eagle's medium (Invitrogen)
supplemented with 10% heat-inactivated fetal bo-
vine serum (Life Technologies) and 1% Glutamax.
Full-length cDNA encoding for WT KDM5B or the
catalytically inactive variant KDM5B H499A/E501A,
both with a 3*FLAG N-terminal tag, was inserted into
the pCDNA5-FRT-TO-3FLAG vector to ectopically
overexpress the genes [50]. Cells were transiently
transfected using cDNA and Lipofectamine 3000
(Life Technologies). Four hours after transfection,
the cells were subjected to treatment with serial
dilutions of compound. After 24 h, the cells were
fixed with 4% formaldehyde and stained with anti-
Flag antibody (Sigma F3165), an anti-methylated
histone antibody (H3K4me3 DiagenodeC15410003).
The cells were then stained with secondary anti-
bodies [Alexa Fluor 488 and Alexa Fluor 568-labeled
(Life Technologies)] and 4’,6-diamidino-2-phenylin-
dole. Image acquisition was conducted using Oper-
etta High Content Imaging System (PerkinElmer),
and image analysis was performed using the
Columbus software (PerkinElmer). Aminimum thresh-
old for anti-Flag intensity was set to ensure that
only cells highly producing the demethylase were
analyzed.Synthesis of esters of TCA cycle intermediates
and KDOAM-25
KDOAM-25 was kindly provided by Dr.
Gian-Filippo Ruda and Prof. Paul Brennan (Target
Discovery Institute, Structural Genomics Consor-
tium, University of Oxford) [55]. Dimethyl-L-2HG
and dimethyl-D-2HG were synthesized according to
t h e d e s c r i b e d p r o c e d u r e s [ 2 8 , 5 5 ] .
Dimethyl-2-oxoglutarate, dimethylsuccinate and
d ime thy l f umara te were pu rchased f rom
Sigma-Aldrich, and octyl-L-2HG and octyl-D-2HG
were purchased from Cambridge Bioscience.
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5FUP (2OG), 5FY4 (succinate), 5FY5 (fumarate),
5FYV (oxaloacetate), 5FY9 (pyruvate), 5FZ8
(malate), 5FYS (D-2-hydroxygutarate), 5FZD (L-2-
hydroxyglutarate).Acknowledgments
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